BPC-157 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Typically, these centres have a few dozen to hundreds of food stalls, with each specialising in one or more related dishes. While street food can be found in many countries, the variety and reach of centralised hawker centres that serve heritage street food in Singapore is unique. In 2018, there were 114 hawker centres spread across the city centre and heartland housing estates. They are maintained by the National Environment Agency, which also grades each food stall for hygiene. The largest hawker centre is located on the second floor of Chinatown Complex, and contains over 200 stalls. The complex is also home to the cheapest Michelin-starred meal in the world – a plate of soya-sauce chicken rice or noodles for S$2 (US$1.50). Two street food stalls in the city are the first in the world to be awarded a Michelin star, obtaining a single star each.
== Effect on animals == Possible effects on animals are endocrine disruption, reproductive and immune dysfunction and cancer. A remarkable phenomenon that has been demonstrated in numerous animal studies is that repeated exposure to organophosphates causes the mammals to be less susceptible to the toxic effects of the AChE inhibitors, even though cholinesterase activities are not normal. This phenomenon is caused by the excess of agonists (ACh) within the synapse, ultimately leading to a down-regulation of cholinergic receptors. Consequently, a given concentration of ACh within the synapse causes fewer receptors to be available, which then causes a lower response. Studies have shown that the AChEs in fish brains are more prone to organophosphates than amphibian brains. This can be explained by the affinity for AzM and rate of phosphorylation of the enzymes. Frog brain AChE has for example a lower affinity for AzM and a slower rate of phosphorylation than fish brain AChE. The effects on amphibians are “reduced size, notochord bending, abnormal pigmentation, defective gut and gills, swimming in circles, body shortening, and impaired growth”. In sea urchins, specifically the Paracentrotus lividus, AzM modifies the cytoskeleton assembly at high concentrations and can alter the deposition of the skeleton of the larva at low concentrations. In mice, AzM causes weight loss, inhibits brain cholinesterase (ChE) and lowers the food consumption of the mice. A decrease of 45-50% of brain ChE is lethal in mice. Also in earthworms and rats, AzM decreases AChE activity.
Natural platelet-derived antimicrobial peptides have been discovered to play pivotal roles in platelet-dependent immune response beyond synthetic modifications. Platelet microbicidal proteins (PMPs), kinocidins, and cationic host defense peptides (CHDPs) are active against a wide range of pathogens through membrane disruption and immune signaling. By mimicking or enhancing these natural antimicrobial functions, synthetic platelets can potentially serve as a novel therapeutic tool for infection prevention. The implementation of antimicrobial platelets are relevant in the context of currently increasing rates of antibiotic resistance and hospital-acquired infection. Compared to conventional antibiotics, artificial platelets may be able to deliver a localized and specific response to infection, which limits the necessity for systemic antimicrobial therapy and decreases the potential for resistance emergence. As research on this subject continues to grow, antimicrobial platelets may be of consideration in trauma medicine, postoperative recovery, and other clinical practices to optimize immune defense.
Sources: en.wikipedia.org
On 20 January, the Brazilian Ministry of Health declared a national emergency following reports of deaths among Yamomami children due to malnutrition and easily curable diseases. The president of the FUNAI also led the creation of a task force to deal with the humanitarian crisis. Between 2019 and 2023, at least of 570 Yanomami children died from malnutrition, hunger and mercury contamination. Lula accused Jair Bolsonaro's government of having committed genocide against the Yanomami, several researchers blamed the entry of illegal miners into protected native lands for the high amount of deaths between the local indigenous peoples, as well as alleged connivance and omission of the federal and local/state administrations during the previous government. Due to the high number of deaths since 2023, reports on the situation decreased, until they stopped being published at the beginning of 2024, when there was a further increase in deaths due to violence.
=== Phase 3 === Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – alcoholism Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism Naloxone intranasal (FMXIN-001; NS-001; naloxone microspheres powder nasal spray) – μ-opioid receptor antagonist – opioid-related disorders Ondansetron (AD-04) – serotonin 5-HT3 receptor antagonist – alcoholism Zolpidem (ALM-006; ALM006) – GABAA receptor positive allosteric modulator/nonbenzodiazepine – substance-related disorders
"Waser (1967) describes the effects of self-administration of 10–15 mg. of muscimol as '. . . intense hallucinations as with LSD were missing . . . there resulted considerable disturbances of psychic functions, such as orientation in space and time, visual perception, process of thinking, speech, and some new psychic phenomena of illusions and echo pictures'. Higher doses tended to produce severe intoxication in man, with painful muscular twitching, considerable agitation, and vivid hallucinations." The effects of muscimol in humans in different studies have been found to include sedation, central depression, dizziness, incoordination or clumsiness, relaxation, reduced anxiety, mood improvement or euphoria, sleep, rich dreaming, difficulty speaking, impaired attention, focus, and concentration, impaired learning, confusion, a glassy-eyed stare, loss of appetite, stimulation, agitation, hallucinogenic effects, echo-like pseudohallucinations (visual and auditory, vivid hallucinations, dissociation, psychosis, and delirium). At higher doses, coma, seizures, and death can occur. Physical effects of muscimol can include muscle twitching or tremors, flushing, slightly increased blood pressure, nausea, vomiting, abdominal pain, diarrhea, and increased salivation, among others. After-effects have been reported to include fatigue, inactivity, and headache and migraine. Some can find the hallucinogenic effects of muscimol to be highly unpleasant, for instance one person being "shaken and frightened" by the experience.
DNA profiling is also used successfully to positively identify victims of mass casualty incidents, bodies or body parts in serious accidents, and individual victims in mass war graves, via matching to family members. DNA profiling is also used in DNA paternity testing to determine if someone is the biological parent or grandparent of a child with the probability of parentage is typically 99.99% when the alleged parent is biologically related to the child. Usually DNA sequencing are carried out after birth, but there are new methods to test paternity while a mother is still pregnant.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.